Global Recombinant Glycosylated Proteins Biosimilar Supply, Demand and Key Producers, 2023-2029
The global Recombinant Glycosylated Proteins Biosimilar market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
This report studies the global Recombinant Glycosylated Proteins Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Recombinant Glycosylated Proteins Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Recombinant Glycosylated Proteins Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Recombinant Glycosylated Proteins Biosimilar total production and demand, 2018-2029, (K Units)
Global Recombinant Glycosylated Proteins Biosimilar total production value, 2018-2029, (USD Million)
Global Recombinant Glycosylated Proteins Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Recombinant Glycosylated Proteins Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Recombinant Glycosylated Proteins Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Recombinant Glycosylated Proteins Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Recombinant Glycosylated Proteins Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Recombinant Glycosylated Proteins Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Recombinant Glycosylated Proteins Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion Inc., Amgen, Inc. and STADA Arzneimittel AG, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Recombinant Glycosylated Proteins Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Recombinant Glycosylated Proteins Biosimilar Market, By Region:
1. How big is the global Recombinant Glycosylated Proteins Biosimilar market?
2. What is the demand of the global Recombinant Glycosylated Proteins Biosimilar market?
3. What is the year over year growth of the global Recombinant Glycosylated Proteins Biosimilar market?
4. What is the production and production value of the global Recombinant Glycosylated Proteins Biosimilar market?
5. Who are the key producers in the global Recombinant Glycosylated Proteins Biosimilar market?
6. What are the growth factors driving the market demand?
This report studies the global Recombinant Glycosylated Proteins Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Recombinant Glycosylated Proteins Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Recombinant Glycosylated Proteins Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Recombinant Glycosylated Proteins Biosimilar total production and demand, 2018-2029, (K Units)
Global Recombinant Glycosylated Proteins Biosimilar total production value, 2018-2029, (USD Million)
Global Recombinant Glycosylated Proteins Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Recombinant Glycosylated Proteins Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Recombinant Glycosylated Proteins Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Recombinant Glycosylated Proteins Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Recombinant Glycosylated Proteins Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Recombinant Glycosylated Proteins Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Recombinant Glycosylated Proteins Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion Inc., Amgen, Inc. and STADA Arzneimittel AG, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Recombinant Glycosylated Proteins Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Recombinant Glycosylated Proteins Biosimilar Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Monoclonal Antibodies
- Erythropoietin
- Others
- Chronic Diseases
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Others
- Pfizer, Inc.
- Intas Pharmaceuticals Ltd.
- Biocon
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH (A Novartis Division)
- Celltrion Inc.
- Amgen, Inc.
- STADA Arzneimittel AG
- Apotex Inc.
1. How big is the global Recombinant Glycosylated Proteins Biosimilar market?
2. What is the demand of the global Recombinant Glycosylated Proteins Biosimilar market?
3. What is the year over year growth of the global Recombinant Glycosylated Proteins Biosimilar market?
4. What is the production and production value of the global Recombinant Glycosylated Proteins Biosimilar market?
5. Who are the key producers in the global Recombinant Glycosylated Proteins Biosimilar market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Recombinant Glycosylated Proteins Biosimilar Introduction
1.2 World Recombinant Glycosylated Proteins Biosimilar Supply & Forecast
1.2.1 World Recombinant Glycosylated Proteins Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.2.3 World Recombinant Glycosylated Proteins Biosimilar Pricing Trends (2018-2029)
1.3 World Recombinant Glycosylated Proteins Biosimilar Production by Region (Based on Production Site)
1.3.1 World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2018-2029)
1.3.2 World Recombinant Glycosylated Proteins Biosimilar Production by Region (2018-2029)
1.3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.3.5 Europe Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.3.6 China Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.3.7 Japan Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Recombinant Glycosylated Proteins Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Recombinant Glycosylated Proteins Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Recombinant Glycosylated Proteins Biosimilar Demand (2018-2029)
2.2 World Recombinant Glycosylated Proteins Biosimilar Consumption by Region
2.2.1 World Recombinant Glycosylated Proteins Biosimilar Consumption by Region (2018-2023)
2.2.2 World Recombinant Glycosylated Proteins Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.4 China Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.5 Europe Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.6 Japan Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.7 South Korea Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.8 ASEAN Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.9 India Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
3 WORLD RECOMBINANT GLYCOSYLATED PROTEINS BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Recombinant Glycosylated Proteins Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Recombinant Glycosylated Proteins Biosimilar Production by Manufacturer (2018-2023)
3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Recombinant Glycosylated Proteins Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Recombinant Glycosylated Proteins Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Recombinant Glycosylated Proteins Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Recombinant Glycosylated Proteins Biosimilar in 2022
3.6 Recombinant Glycosylated Proteins Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Recombinant Glycosylated Proteins Biosimilar Market: Region Footprint
3.6.2 Recombinant Glycosylated Proteins Biosimilar Market: Company Product Type Footprint
3.6.3 Recombinant Glycosylated Proteins Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Comparison
4.1.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Comparison
4.2.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Comparison
4.3.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Recombinant Glycosylated Proteins Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023)
4.5 China Based Recombinant Glycosylated Proteins Biosimilar Manufacturers and Market Share
4.5.1 China Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023)
4.6 Rest of World Based Recombinant Glycosylated Proteins Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Recombinant Glycosylated Proteins Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Monoclonal Antibodies
5.2.2 Erythropoietin
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Recombinant Glycosylated Proteins Biosimilar Production by Type (2018-2029)
5.3.2 World Recombinant Glycosylated Proteins Biosimilar Production Value by Type (2018-2029)
5.3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Recombinant Glycosylated Proteins Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Chronic Diseases
6.2.2 Oncology
6.2.3 Autoimmune Diseases
6.2.4 Infectious Diseases
6.2.5 Blood Disorders
6.2.6 Growth Hormone Deficiency
6.2.7 Others
6.3 Market Segment by Application
6.3.1 World Recombinant Glycosylated Proteins Biosimilar Production by Application (2018-2029)
6.3.2 World Recombinant Glycosylated Proteins Biosimilar Production Value by Application (2018-2029)
6.3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Pfizer, Inc.
7.1.1 Pfizer, Inc. Details
7.1.2 Pfizer, Inc. Major Business
7.1.3 Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.1.4 Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer, Inc. Recent Developments/Updates
7.1.6 Pfizer, Inc. Competitive Strengths & Weaknesses
7.2 Intas Pharmaceuticals Ltd.
7.2.1 Intas Pharmaceuticals Ltd. Details
7.2.2 Intas Pharmaceuticals Ltd. Major Business
7.2.3 Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.2.4 Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Intas Pharmaceuticals Ltd. Recent Developments/Updates
7.2.6 Intas Pharmaceuticals Ltd. Competitive Strengths & Weaknesses
7.3 Biocon
7.3.1 Biocon Details
7.3.2 Biocon Major Business
7.3.3 Biocon Recombinant Glycosylated Proteins Biosimilar Product and Services
7.3.4 Biocon Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Biocon Recent Developments/Updates
7.3.6 Biocon Competitive Strengths & Weaknesses
7.4 Dr. Reddy’s Laboratories Ltd.
7.4.1 Dr. Reddy’s Laboratories Ltd. Details
7.4.2 Dr. Reddy’s Laboratories Ltd. Major Business
7.4.3 Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.4.4 Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
7.4.6 Dr. Reddy’s Laboratories Ltd. Competitive Strengths & Weaknesses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Teva Pharmaceutical Industries Ltd. Details
7.5.2 Teva Pharmaceutical Industries Ltd. Major Business
7.5.3 Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.5.4 Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
7.5.6 Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
7.6 Sandoz International GmbH (A Novartis Division)
7.6.1 Sandoz International GmbH (A Novartis Division) Details
7.6.2 Sandoz International GmbH (A Novartis Division) Major Business
7.6.3 Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Product and Services
7.6.4 Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Sandoz International GmbH (A Novartis Division) Recent Developments/Updates
7.6.6 Sandoz International GmbH (A Novartis Division) Competitive Strengths & Weaknesses
7.7 Celltrion Inc.
7.7.1 Celltrion Inc. Details
7.7.2 Celltrion Inc. Major Business
7.7.3 Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.7.4 Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Celltrion Inc. Recent Developments/Updates
7.7.6 Celltrion Inc. Competitive Strengths & Weaknesses
7.8 Amgen, Inc.
7.8.1 Amgen, Inc. Details
7.8.2 Amgen, Inc. Major Business
7.8.3 Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.8.4 Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Amgen, Inc. Recent Developments/Updates
7.8.6 Amgen, Inc. Competitive Strengths & Weaknesses
7.9 STADA Arzneimittel AG
7.9.1 STADA Arzneimittel AG Details
7.9.2 STADA Arzneimittel AG Major Business
7.9.3 STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Product and Services
7.9.4 STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 STADA Arzneimittel AG Recent Developments/Updates
7.9.6 STADA Arzneimittel AG Competitive Strengths & Weaknesses
7.10 Apotex Inc.
7.10.1 Apotex Inc. Details
7.10.2 Apotex Inc. Major Business
7.10.3 Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.10.4 Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Apotex Inc. Recent Developments/Updates
7.10.6 Apotex Inc. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Recombinant Glycosylated Proteins Biosimilar Industry Chain
8.2 Recombinant Glycosylated Proteins Biosimilar Upstream Analysis
8.2.1 Recombinant Glycosylated Proteins Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Recombinant Glycosylated Proteins Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Recombinant Glycosylated Proteins Biosimilar Production Mode
8.6 Recombinant Glycosylated Proteins Biosimilar Procurement Model
8.7 Recombinant Glycosylated Proteins Biosimilar Industry Sales Model and Sales Channels
8.7.1 Recombinant Glycosylated Proteins Biosimilar Sales Model
8.7.2 Recombinant Glycosylated Proteins Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Recombinant Glycosylated Proteins Biosimilar Introduction
1.2 World Recombinant Glycosylated Proteins Biosimilar Supply & Forecast
1.2.1 World Recombinant Glycosylated Proteins Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.2.3 World Recombinant Glycosylated Proteins Biosimilar Pricing Trends (2018-2029)
1.3 World Recombinant Glycosylated Proteins Biosimilar Production by Region (Based on Production Site)
1.3.1 World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2018-2029)
1.3.2 World Recombinant Glycosylated Proteins Biosimilar Production by Region (2018-2029)
1.3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.3.5 Europe Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.3.6 China Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.3.7 Japan Recombinant Glycosylated Proteins Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Recombinant Glycosylated Proteins Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Recombinant Glycosylated Proteins Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Recombinant Glycosylated Proteins Biosimilar Demand (2018-2029)
2.2 World Recombinant Glycosylated Proteins Biosimilar Consumption by Region
2.2.1 World Recombinant Glycosylated Proteins Biosimilar Consumption by Region (2018-2023)
2.2.2 World Recombinant Glycosylated Proteins Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.4 China Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.5 Europe Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.6 Japan Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.7 South Korea Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.8 ASEAN Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
2.9 India Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029)
3 WORLD RECOMBINANT GLYCOSYLATED PROTEINS BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Recombinant Glycosylated Proteins Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Recombinant Glycosylated Proteins Biosimilar Production by Manufacturer (2018-2023)
3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Recombinant Glycosylated Proteins Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Recombinant Glycosylated Proteins Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Recombinant Glycosylated Proteins Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Recombinant Glycosylated Proteins Biosimilar in 2022
3.6 Recombinant Glycosylated Proteins Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Recombinant Glycosylated Proteins Biosimilar Market: Region Footprint
3.6.2 Recombinant Glycosylated Proteins Biosimilar Market: Company Product Type Footprint
3.6.3 Recombinant Glycosylated Proteins Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Comparison
4.1.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Comparison
4.2.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Comparison
4.3.1 United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Recombinant Glycosylated Proteins Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023)
4.5 China Based Recombinant Glycosylated Proteins Biosimilar Manufacturers and Market Share
4.5.1 China Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023)
4.6 Rest of World Based Recombinant Glycosylated Proteins Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Recombinant Glycosylated Proteins Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Monoclonal Antibodies
5.2.2 Erythropoietin
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Recombinant Glycosylated Proteins Biosimilar Production by Type (2018-2029)
5.3.2 World Recombinant Glycosylated Proteins Biosimilar Production Value by Type (2018-2029)
5.3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Recombinant Glycosylated Proteins Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Chronic Diseases
6.2.2 Oncology
6.2.3 Autoimmune Diseases
6.2.4 Infectious Diseases
6.2.5 Blood Disorders
6.2.6 Growth Hormone Deficiency
6.2.7 Others
6.3 Market Segment by Application
6.3.1 World Recombinant Glycosylated Proteins Biosimilar Production by Application (2018-2029)
6.3.2 World Recombinant Glycosylated Proteins Biosimilar Production Value by Application (2018-2029)
6.3.3 World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Pfizer, Inc.
7.1.1 Pfizer, Inc. Details
7.1.2 Pfizer, Inc. Major Business
7.1.3 Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.1.4 Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer, Inc. Recent Developments/Updates
7.1.6 Pfizer, Inc. Competitive Strengths & Weaknesses
7.2 Intas Pharmaceuticals Ltd.
7.2.1 Intas Pharmaceuticals Ltd. Details
7.2.2 Intas Pharmaceuticals Ltd. Major Business
7.2.3 Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.2.4 Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Intas Pharmaceuticals Ltd. Recent Developments/Updates
7.2.6 Intas Pharmaceuticals Ltd. Competitive Strengths & Weaknesses
7.3 Biocon
7.3.1 Biocon Details
7.3.2 Biocon Major Business
7.3.3 Biocon Recombinant Glycosylated Proteins Biosimilar Product and Services
7.3.4 Biocon Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Biocon Recent Developments/Updates
7.3.6 Biocon Competitive Strengths & Weaknesses
7.4 Dr. Reddy’s Laboratories Ltd.
7.4.1 Dr. Reddy’s Laboratories Ltd. Details
7.4.2 Dr. Reddy’s Laboratories Ltd. Major Business
7.4.3 Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.4.4 Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
7.4.6 Dr. Reddy’s Laboratories Ltd. Competitive Strengths & Weaknesses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Teva Pharmaceutical Industries Ltd. Details
7.5.2 Teva Pharmaceutical Industries Ltd. Major Business
7.5.3 Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.5.4 Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
7.5.6 Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
7.6 Sandoz International GmbH (A Novartis Division)
7.6.1 Sandoz International GmbH (A Novartis Division) Details
7.6.2 Sandoz International GmbH (A Novartis Division) Major Business
7.6.3 Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Product and Services
7.6.4 Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Sandoz International GmbH (A Novartis Division) Recent Developments/Updates
7.6.6 Sandoz International GmbH (A Novartis Division) Competitive Strengths & Weaknesses
7.7 Celltrion Inc.
7.7.1 Celltrion Inc. Details
7.7.2 Celltrion Inc. Major Business
7.7.3 Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.7.4 Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Celltrion Inc. Recent Developments/Updates
7.7.6 Celltrion Inc. Competitive Strengths & Weaknesses
7.8 Amgen, Inc.
7.8.1 Amgen, Inc. Details
7.8.2 Amgen, Inc. Major Business
7.8.3 Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.8.4 Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Amgen, Inc. Recent Developments/Updates
7.8.6 Amgen, Inc. Competitive Strengths & Weaknesses
7.9 STADA Arzneimittel AG
7.9.1 STADA Arzneimittel AG Details
7.9.2 STADA Arzneimittel AG Major Business
7.9.3 STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Product and Services
7.9.4 STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 STADA Arzneimittel AG Recent Developments/Updates
7.9.6 STADA Arzneimittel AG Competitive Strengths & Weaknesses
7.10 Apotex Inc.
7.10.1 Apotex Inc. Details
7.10.2 Apotex Inc. Major Business
7.10.3 Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
7.10.4 Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Apotex Inc. Recent Developments/Updates
7.10.6 Apotex Inc. Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Recombinant Glycosylated Proteins Biosimilar Industry Chain
8.2 Recombinant Glycosylated Proteins Biosimilar Upstream Analysis
8.2.1 Recombinant Glycosylated Proteins Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Recombinant Glycosylated Proteins Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Recombinant Glycosylated Proteins Biosimilar Production Mode
8.6 Recombinant Glycosylated Proteins Biosimilar Procurement Model
8.7 Recombinant Glycosylated Proteins Biosimilar Industry Sales Model and Sales Channels
8.7.1 Recombinant Glycosylated Proteins Biosimilar Sales Model
8.7.2 Recombinant Glycosylated Proteins Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Recombinant Glycosylated Proteins Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Recombinant Glycosylated Proteins Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Recombinant Glycosylated Proteins Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Recombinant Glycosylated Proteins Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Recombinant Glycosylated Proteins Biosimilar Major Market Trends
Table 13. World Recombinant Glycosylated Proteins Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Recombinant Glycosylated Proteins Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Recombinant Glycosylated Proteins Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Recombinant Glycosylated Proteins Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Recombinant Glycosylated Proteins Biosimilar Producers in 2022
Table 18. World Recombinant Glycosylated Proteins Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Recombinant Glycosylated Proteins Biosimilar Producers in 2022
Table 20. World Recombinant Glycosylated Proteins Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Recombinant Glycosylated Proteins Biosimilar Company Evaluation Quadrant
Table 22. World Recombinant Glycosylated Proteins Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Recombinant Glycosylated Proteins Biosimilar Production Site of Key Manufacturer
Table 24. Recombinant Glycosylated Proteins Biosimilar Market: Company Product Type Footprint
Table 25. Recombinant Glycosylated Proteins Biosimilar Market: Company Product Application Footprint
Table 26. Recombinant Glycosylated Proteins Biosimilar Competitive Factors
Table 27. Recombinant Glycosylated Proteins Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Recombinant Glycosylated Proteins Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Recombinant Glycosylated Proteins Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Recombinant Glycosylated Proteins Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Recombinant Glycosylated Proteins Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share (2018-2023)
Table 37. China Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share (2018-2023)
Table 47. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Recombinant Glycosylated Proteins Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Recombinant Glycosylated Proteins Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Recombinant Glycosylated Proteins Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Recombinant Glycosylated Proteins Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Pfizer, Inc. Major Business
Table 63. Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 64. Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Pfizer, Inc. Recent Developments/Updates
Table 66. Pfizer, Inc. Competitive Strengths & Weaknesses
Table 67. Intas Pharmaceuticals Ltd. Basic Information, Manufacturing Base and Competitors
Table 68. Intas Pharmaceuticals Ltd. Major Business
Table 69. Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 70. Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Intas Pharmaceuticals Ltd. Recent Developments/Updates
Table 72. Intas Pharmaceuticals Ltd. Competitive Strengths & Weaknesses
Table 73. Biocon Basic Information, Manufacturing Base and Competitors
Table 74. Biocon Major Business
Table 75. Biocon Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 76. Biocon Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Biocon Recent Developments/Updates
Table 78. Biocon Competitive Strengths & Weaknesses
Table 79. Dr. Reddy’s Laboratories Ltd. Basic Information, Manufacturing Base and Competitors
Table 80. Dr. Reddy’s Laboratories Ltd. Major Business
Table 81. Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 82. Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
Table 84. Dr. Reddy’s Laboratories Ltd. Competitive Strengths & Weaknesses
Table 85. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 86. Teva Pharmaceutical Industries Ltd. Major Business
Table 87. Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 88. Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 90. Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
Table 91. Sandoz International GmbH (A Novartis Division) Basic Information, Manufacturing Base and Competitors
Table 92. Sandoz International GmbH (A Novartis Division) Major Business
Table 93. Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 94. Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Sandoz International GmbH (A Novartis Division) Recent Developments/Updates
Table 96. Sandoz International GmbH (A Novartis Division) Competitive Strengths & Weaknesses
Table 97. Celltrion Inc. Basic Information, Manufacturing Base and Competitors
Table 98. Celltrion Inc. Major Business
Table 99. Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 100. Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Celltrion Inc. Recent Developments/Updates
Table 102. Celltrion Inc. Competitive Strengths & Weaknesses
Table 103. Amgen, Inc. Basic Information, Manufacturing Base and Competitors
Table 104. Amgen, Inc. Major Business
Table 105. Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 106. Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Amgen, Inc. Recent Developments/Updates
Table 108. Amgen, Inc. Competitive Strengths & Weaknesses
Table 109. STADA Arzneimittel AG Basic Information, Manufacturing Base and Competitors
Table 110. STADA Arzneimittel AG Major Business
Table 111. STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 112. STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. STADA Arzneimittel AG Recent Developments/Updates
Table 114. Apotex Inc. Basic Information, Manufacturing Base and Competitors
Table 115. Apotex Inc. Major Business
Table 116. Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 117. Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Recombinant Glycosylated Proteins Biosimilar Upstream (Raw Materials)
Table 119. Recombinant Glycosylated Proteins Biosimilar Typical Customers
Table 120. Recombinant Glycosylated Proteins Biosimilar Typical Distributors
Table 1. World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Recombinant Glycosylated Proteins Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Recombinant Glycosylated Proteins Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Recombinant Glycosylated Proteins Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Recombinant Glycosylated Proteins Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Recombinant Glycosylated Proteins Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Recombinant Glycosylated Proteins Biosimilar Major Market Trends
Table 13. World Recombinant Glycosylated Proteins Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Recombinant Glycosylated Proteins Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Recombinant Glycosylated Proteins Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Recombinant Glycosylated Proteins Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Recombinant Glycosylated Proteins Biosimilar Producers in 2022
Table 18. World Recombinant Glycosylated Proteins Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Recombinant Glycosylated Proteins Biosimilar Producers in 2022
Table 20. World Recombinant Glycosylated Proteins Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Recombinant Glycosylated Proteins Biosimilar Company Evaluation Quadrant
Table 22. World Recombinant Glycosylated Proteins Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Recombinant Glycosylated Proteins Biosimilar Production Site of Key Manufacturer
Table 24. Recombinant Glycosylated Proteins Biosimilar Market: Company Product Type Footprint
Table 25. Recombinant Glycosylated Proteins Biosimilar Market: Company Product Application Footprint
Table 26. Recombinant Glycosylated Proteins Biosimilar Competitive Factors
Table 27. Recombinant Glycosylated Proteins Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Recombinant Glycosylated Proteins Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Recombinant Glycosylated Proteins Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Recombinant Glycosylated Proteins Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Recombinant Glycosylated Proteins Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share (2018-2023)
Table 37. China Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Recombinant Glycosylated Proteins Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share (2018-2023)
Table 47. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Recombinant Glycosylated Proteins Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Recombinant Glycosylated Proteins Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Recombinant Glycosylated Proteins Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Recombinant Glycosylated Proteins Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Pfizer, Inc. Major Business
Table 63. Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 64. Pfizer, Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Pfizer, Inc. Recent Developments/Updates
Table 66. Pfizer, Inc. Competitive Strengths & Weaknesses
Table 67. Intas Pharmaceuticals Ltd. Basic Information, Manufacturing Base and Competitors
Table 68. Intas Pharmaceuticals Ltd. Major Business
Table 69. Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 70. Intas Pharmaceuticals Ltd. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Intas Pharmaceuticals Ltd. Recent Developments/Updates
Table 72. Intas Pharmaceuticals Ltd. Competitive Strengths & Weaknesses
Table 73. Biocon Basic Information, Manufacturing Base and Competitors
Table 74. Biocon Major Business
Table 75. Biocon Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 76. Biocon Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Biocon Recent Developments/Updates
Table 78. Biocon Competitive Strengths & Weaknesses
Table 79. Dr. Reddy’s Laboratories Ltd. Basic Information, Manufacturing Base and Competitors
Table 80. Dr. Reddy’s Laboratories Ltd. Major Business
Table 81. Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 82. Dr. Reddy’s Laboratories Ltd. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Dr. Reddy’s Laboratories Ltd. Recent Developments/Updates
Table 84. Dr. Reddy’s Laboratories Ltd. Competitive Strengths & Weaknesses
Table 85. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 86. Teva Pharmaceutical Industries Ltd. Major Business
Table 87. Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 88. Teva Pharmaceutical Industries Ltd. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 90. Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
Table 91. Sandoz International GmbH (A Novartis Division) Basic Information, Manufacturing Base and Competitors
Table 92. Sandoz International GmbH (A Novartis Division) Major Business
Table 93. Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 94. Sandoz International GmbH (A Novartis Division) Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Sandoz International GmbH (A Novartis Division) Recent Developments/Updates
Table 96. Sandoz International GmbH (A Novartis Division) Competitive Strengths & Weaknesses
Table 97. Celltrion Inc. Basic Information, Manufacturing Base and Competitors
Table 98. Celltrion Inc. Major Business
Table 99. Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 100. Celltrion Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Celltrion Inc. Recent Developments/Updates
Table 102. Celltrion Inc. Competitive Strengths & Weaknesses
Table 103. Amgen, Inc. Basic Information, Manufacturing Base and Competitors
Table 104. Amgen, Inc. Major Business
Table 105. Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 106. Amgen, Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Amgen, Inc. Recent Developments/Updates
Table 108. Amgen, Inc. Competitive Strengths & Weaknesses
Table 109. STADA Arzneimittel AG Basic Information, Manufacturing Base and Competitors
Table 110. STADA Arzneimittel AG Major Business
Table 111. STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 112. STADA Arzneimittel AG Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. STADA Arzneimittel AG Recent Developments/Updates
Table 114. Apotex Inc. Basic Information, Manufacturing Base and Competitors
Table 115. Apotex Inc. Major Business
Table 116. Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Product and Services
Table 117. Apotex Inc. Recombinant Glycosylated Proteins Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Recombinant Glycosylated Proteins Biosimilar Upstream (Raw Materials)
Table 119. Recombinant Glycosylated Proteins Biosimilar Typical Customers
Table 120. Recombinant Glycosylated Proteins Biosimilar Typical Distributors
LIST OF FIGURES
Figure 1. Recombinant Glycosylated Proteins Biosimilar Picture
Figure 2. World Recombinant Glycosylated Proteins Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Recombinant Glycosylated Proteins Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Recombinant Glycosylated Proteins Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 12. Recombinant Glycosylated Proteins Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Recombinant Glycosylated Proteins Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Recombinant Glycosylated Proteins Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Recombinant Glycosylated Proteins Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Recombinant Glycosylated Proteins Biosimilar Markets in 2022
Figure 26. United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share 2022
Figure 32. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Type in 2022
Figure 34. Monoclonal Antibodies
Figure 35. Erythropoietin
Figure 36. Others
Figure 37. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Type (2018-2029)
Figure 38. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Type (2018-2029)
Figure 39. World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Application in 2022
Figure 42. Chronic Diseases
Figure 43. Oncology
Figure 44. Autoimmune Diseases
Figure 45. Infectious Diseases
Figure 46. Blood Disorders
Figure 47. Growth Hormone Deficiency
Figure 48. Others
Figure 49. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Application (2018-2029)
Figure 50. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Application (2018-2029)
Figure 51. World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 52. Recombinant Glycosylated Proteins Biosimilar Industry Chain
Figure 53. Recombinant Glycosylated Proteins Biosimilar Procurement Model
Figure 54. Recombinant Glycosylated Proteins Biosimilar Sales Model
Figure 55. Recombinant Glycosylated Proteins Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 56. Methodology
Figure 57. Research Process and Data Source
Figure 1. Recombinant Glycosylated Proteins Biosimilar Picture
Figure 2. World Recombinant Glycosylated Proteins Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Recombinant Glycosylated Proteins Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Recombinant Glycosylated Proteins Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Recombinant Glycosylated Proteins Biosimilar Production (2018-2029) & (K Units)
Figure 12. Recombinant Glycosylated Proteins Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Recombinant Glycosylated Proteins Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Recombinant Glycosylated Proteins Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Recombinant Glycosylated Proteins Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Recombinant Glycosylated Proteins Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Recombinant Glycosylated Proteins Biosimilar Markets in 2022
Figure 26. United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Recombinant Glycosylated Proteins Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Recombinant Glycosylated Proteins Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Recombinant Glycosylated Proteins Biosimilar Production Market Share 2022
Figure 32. World Recombinant Glycosylated Proteins Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Type in 2022
Figure 34. Monoclonal Antibodies
Figure 35. Erythropoietin
Figure 36. Others
Figure 37. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Type (2018-2029)
Figure 38. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Type (2018-2029)
Figure 39. World Recombinant Glycosylated Proteins Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 40. World Recombinant Glycosylated Proteins Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 41. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Application in 2022
Figure 42. Chronic Diseases
Figure 43. Oncology
Figure 44. Autoimmune Diseases
Figure 45. Infectious Diseases
Figure 46. Blood Disorders
Figure 47. Growth Hormone Deficiency
Figure 48. Others
Figure 49. World Recombinant Glycosylated Proteins Biosimilar Production Market Share by Application (2018-2029)
Figure 50. World Recombinant Glycosylated Proteins Biosimilar Production Value Market Share by Application (2018-2029)
Figure 51. World Recombinant Glycosylated Proteins Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 52. Recombinant Glycosylated Proteins Biosimilar Industry Chain
Figure 53. Recombinant Glycosylated Proteins Biosimilar Procurement Model
Figure 54. Recombinant Glycosylated Proteins Biosimilar Sales Model
Figure 55. Recombinant Glycosylated Proteins Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 56. Methodology
Figure 57. Research Process and Data Source
